首页> 外文期刊>Journal of Clinical Medicine >Mitophagy in Cardiovascular Diseases
【24h】

Mitophagy in Cardiovascular Diseases

机译:心血管疾病中的水墨

获取原文
       

摘要

Cardiovascular diseases are one of the leading causes of death. Increasing evidence has shown that pharmacological or genetic targeting of mitochondria can ameliorate each stage of these pathologies, which are strongly associated with mitochondrial dysfunction. Removal of inefficient and dysfunctional mitochondria through the process of mitophagy has been reported to be essential for meeting the energetic requirements and maintaining the biochemical homeostasis of cells. This process is useful for counteracting the negative phenotypic changes that occur during cardiovascular diseases, and understanding the molecular players involved might be crucial for the development of potential therapies. Here, we summarize the current knowledge on mitophagy (and autophagy) mechanisms in the context of heart disease with an important focus on atherosclerosis, ischemic heart disease, cardiomyopathies, heart failure, hypertension, arrhythmia, congenital heart disease and peripheral vascular disease. We aim to provide a complete background on the mechanisms of action of this mitochondrial quality control process in cardiology and in cardiac surgery by also reviewing studies on the use of known compounds able to modulate mitophagy for cardioprotective purposes.
机译:心血管疾病是死亡原因之一。增加的证据表明,线粒体的药理学或遗传靶向可以改善这些病理的每个阶段,这与线粒体功能障碍密切相关。据报道,去除效率低下和功能障碍的线粒体,对于满足能量要求并维持细胞的生化稳态至关重要。该过程可用于抵消心血管疾病期间发生的负面表型变化,并且了解所涉及的分子参与者对潜在疗法的发展至关重要。在这里,我们总结了在心脏病的背景下的目前关于肠系古(和自噬)机制的知识,具有重要的关注动脉粥样硬化,缺血性心脏病,心肌病,心力衰竭,高血压,心律失常,先天性心脏病和外周血管疾病。我们的目标是通过审查能够调节心脏保护目的的乳化物的使用的使用方法,为心脏病学和心脏手术中的这种线粒体质量控制过程和心脏手术提供完整的背景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号